PFSA earnings analysis
What we found in PFSA's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
The supplied 10-Q extract does not provide quarterly revenue, EPS, margins, segment results, balance-sheet figures or cash-flow data, so no operating trend can be assessed. The most material disclosures are 3 unremediated internal-control weaknesses and substantial financing and dilution risks associated with the proposed G3 transaction and outstanding securities. No quantitative operating guidance was provided.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Three control weaknesses remain unremediated
- Management concluded internal controls over financial reporting were not effective as of June 30, 2026, citing 3 unremediated material weaknesses: segregation of duties, financial-instrument valuation review expertise, and technical GAAP accounting expertise.
- G3 deal requires at least $30 million financing
- The proposed G3 acquisition requires consummating or securing commitments for financing with aggregate gross proceeds of at least $30.0 million, along with other stockholder, Nasdaq, lender and documentation conditions.
- G3 transaction increases issued securities
- In connection with the G3 option agreement, Profusa issued sellers 201,120 common shares and 52,903.566 Series A preferred shares on July 31, 2026.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- G3 acquisition completion and financing risk
- The G3 acquisition option may not be exercised or completed; it expires 90 days after the target companies provide specified audited and reviewed financial information and requires at least $30.0 million of financing. If the transaction fails, Profusa may incur costs and retain the 201,120 common shares and 52,903.566 preferred shares issued to sellers without acquiring the targets.
- Potential preferred-stock dilution
- If all currently outstanding Series A preferred stock converts after required approval, approximately 55.9 million common shares would be issuable; if the G3 acquisition closes, sellers could receive an additional 53,918.113 preferred shares convertible into approximately 53.9 million common shares.
- Warrant dilution and anti-dilution risk
- The replacement Ascent Warrant could result in issuance of 33,333 common shares and represented approximately 5.5% of outstanding common stock on a post-exercise, fully diluted basis as of June 30, 2026. The warrant carries a $50.00 exercise price and anti-dilution provisions that may increase dilution in a future below-strike financing.
What they said about what is next.
No quantitative revenue or EPS guidance was provided in the supplied 10-Q extract. The filing discusses the proposed G3 acquisition and financing conditions but does not provide an operating outlook.
The filing reads worse than the one before it.
What came before.
- 10-Q · May 15, 2026
- Profusa, Inc. reported a net loss of $3.5 million for Q1 2026, reflecting a 27% increase in losses compared to the same period in 2025. Operating expenses surged by 181%, driven primarily by substantial increases in…
- 10-K · April 15, 2026
- Profusa completed a SPAC business combination in July 2025 and is a platform-stage digital health company with CE approval for its first product, Lumee Oxygen. The company highlights multi-year R&D investment (> $100…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing PFSA makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever